FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Dillman

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Co-author Network

Publications

TOP 3
Robert O Dillman; Robin E Ellis; Cheryl Mayorga; Edward F McClay; Thomas T Amatruda; Denysha Carbonell; Andrew N Cornforth; Cristina de Leon; Carol DePriest; James M Cubellis
Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Robert O Dillman; Khosrow Mahdavi; Neil M Barth; Louis A VanderMolen; Stephanie E McClure
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?
Robert O Dillman; Gary B Fogel; Patric M Schiltz; Senthamil R Selvan; Andrew N Cornforth; Carol DePriest
Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Dillman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Robert O Dillman; Robin E Ellis; Cheryl Mayorga; Edward F McClay; Thomas T Amatruda; Denysha Carbonell; Andrew N Cornforth; Cristina de Leon; Carol DePriest; James M Cubellis
Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(8):641-9.
2012: Robert O Dillman; Khosrow Mahdavi; Neil M Barth; Louis A VanderMolen; Stephanie E McClure
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?
Cancer biotherapy & radiopharmaceuticals 2012;27(6):337-43.
2011: Robert O Dillman; Gary B Fogel; Patric M Schiltz; Senthamil R Selvan; Andrew N Cornforth; Carol DePriest
Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines.
Cancer biotherapy & radiopharmaceuticals 2011;26(4):407-15.
2011: Robert O Dillman; Warren H Fong; Khosrow K Mahdavi; Neil M Barth; Louis A VanderMolen; Stephanie E McClure
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?
Cancer biotherapy & radiopharmaceuticals 2011;26(3):273-7.
2011: Robert O Dillman; Russell Hafer; Craig Cox; Stephanie E McClure
Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer.
International journal of radiation oncology, biology, physics 2011;79(3):719-23.
2011: A N Cornforth; G Lee; Robert O Dillman
Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial.
Journal of biomedicine & biotechnology 2011;2011():635850.
2011: A N Cornforth; A W Fowler; D J Carbonell; Robert O Dillman
Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival.
Cancer immunology, immunotherapy : CII 2011;60(1):123-31.
2010: Robert O Dillman; Andreea A Nanci; Scott T Williams; Richard B Kim; Russell L Hafer; Colleen L Coleman; Peter C Wang; Christopher M Duma; Peter V Chen; Senthamil R Selvan; Andrew N Cornforth; Carol DePriest
Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine.
Cancer biotherapy & radiopharmaceuticals 2010;25(5):553-7.
2010: Senthamil R Selvan; Denysha J Carbonell; Abner W Fowler; Andrea R Beatty; Mepur H Ravindranath; Robert O Dillman
Establishment of stable cell lines for personalized melanoma cell vaccine.
Melanoma research 2010;20(4):280-92.
2009: Andrew N Cornforth; Gregory J Lee; Abner W Fowler; Denysha J Carbonell; Robert O Dillman
Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy.
Journal of clinical immunology 2009;29(5):657-64.
2009: Robert O Dillman; Senthamil R Selvan; Patric M Schiltz; Edward F McClay; Neil M Barth; Carol DePriest; Cristina de Leon; Cheryl Mayorga; Andrew N Cornforth; Kanoe Allen
Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Cancer biotherapy & radiopharmaceuticals 2009;24(3):311-9.
2009: Robert O Dillman; Kenneth Aaron; F Scott Heinemann; Stephanie E McClure
Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance.
Cancer 2009;115(9):1840-8.
2008: Archana J McEligot; Theresa Im; Robert O Dillman; John G West; Rana Salem; Reina Haque; Hoda Anton-Culver
Abstracting height and weight from medical records, and breast cancer pathologic factors.
Cancer causes & control : CCC 2008;19(10):1217-26.
2008: Robert K Oldham; Robert O Dillman
Monoclonal antibodies in cancer therapy: 25 years of progress.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1774-7.
2008: Patric M Schiltz; Robert O Dillman; Catharina M Korse; James M Cubellis; Gregory J Lee; Gijsbert C De Gast
Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Cancer biotherapy & radiopharmaceuticals 2008;23(2):214-21.
2008: Senthamil R Selvan; Robert O Dillman; Abner W Fowler; Denysha J Carbonell; Mepur H Ravindranath
Monitoring response to treatment in melanoma patients: potential of a serum glycomic marker.
International journal of cancer. Journal international du cancer 2008;122(6):1374-83.
2008: Robert O Dillman
Immunophenotyping of chronic lymphoid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1193-4.
2007: Patric M Schiltz; Gregory J Lee; Jian Gang Zhang; Neil Hoa; H Terry Wepsic; Robert O Dillman; Martin R Jadus
Human allogeneic and murine xenogeneic dendritic cells are cytotoxic to human tumor cells via two distinct pathways.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):672-83.
2007: Robert O Dillman; Carol DePriest; Cristina DeLeon; Neil M Barth; Lee S Schwartzberg; Linda D Beutel; Patric M Schiltz; Shankar K Nayak
Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma.
Cancer biotherapy & radiopharmaceuticals 2007;22(3):309-21.
2007: Robert O Dillman; Marshall T Schreeder; Jeremy K Hon; Elizabeth F Connelly; Carol DePriest; Kathy Cutter
Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Cancer biotherapy & radiopharmaceuticals 2007;22(2):185-93.
2006: Robert O Dillman; Senthamil R Selvan; Patric M Schiltz
Patient-specific dendritic-cell vaccines for metastatic melanoma.
The New England journal of medicine 2006;355(11):1179-81.
2006: Robert O Dillman; Michael C Wiemann; D Fritz Tai; Carol DePriest; Gamini Soori; James J Stark; Khosrow Mahdavi; Curtis K Church
Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.
Cancer biotherapy & radiopharmaceuticals 2006;21(2):130-7.
2005: Robert O Dillman; Sherri D Chico
Cancer patient survival improvement is correlated with the opening of a community cancer center: comparisons with intramural and extramural benchmarks.
Journal of oncology practice / American Society of Clinical Oncology 2005;1(3):84-92.
2005: Robert O Dillman; Linda D Beutel; Shankar Nayak; Carol DePriest; Senthamil R Selvan; Patric M Schiltz
Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes?
Cancer biotherapy & radiopharmaceuticals 2005;20(4):373-8.
2005: Robert O Dillman
American Society of Clinical Oncology 41st annual meeting.
Expert opinion on biological therapy 2005;5(8):1117-27.
2005: Robert O Dillman; Neil M Barth; Louis A VanderMolen; Kanoe Allen; Linda D Beutel; Sherri Chico
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
American journal of clinical oncology 2005;28(3):281-8.
2005: Robert O Dillman
International Society for Biological Therapy for Cancer: 20th anniversary.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(3):169-74.
2005: Senthamil R Selvan; Andrew N Cornforth; Nagesh P Rao; Yvonne A Reid; Patric M Schiltz; Ray P Liao; David T Price; F Scott Heinemann; Robert O Dillman
Establishment and characterization of a human primary prostate carcinoma cell line, HH870.
The Prostate 2005;63(1):91-103.
2004: Robert O Dillman; Patric M Schiltz; Carol DePriest; Neil M Barth; Linda D Beutel; Cristina de Leon; Audrey O'Connor; Shankar Nayak
Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer.
Cancer biotherapy & radiopharmaceuticals 2004;19(6):730-7.
2004: Robert O Dillman; Senthamil R Selvan; Patric M Schiltz; Cheryl Peterson; Kanoe Allen; Carol DePriest; Edward McClay; Neil M Barth; Patric Sheehy; Cristina de Leon; Linda D Beutel
Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.
Cancer biotherapy & radiopharmaceuticals 2004;19(5):658-65.
2004: Robert O Dillman; Neil M Barth; Senthamil R Selvan; Linda D Beutel; Cristina de Leon; Carol DePriest; Cheryl Peterson; Shankar Nayak
Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas.
Cancer biotherapy & radiopharmaceuticals 2004;19(5):581-8.
2004: Robert O Dillman; Neil M Barth; Louis A VanderMolen; Khosrow Mahdavi; Linda D Beutel; Cristina de Leon; Carol DePriest; Shankar Nayak
Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
Cancer biotherapy & radiopharmaceuticals 2004;19(5):570-80.
2004: Robert O Dillman; Christopher M Duma; Patric M Schiltz; Carol DePriest; Robin A Ellis; Kris Okamoto; Linda D Beutel; Cristina de Leon; Sherri Chico
Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(5):398-404.
2004: Patric M Schiltz; Robert O Dillman
A theoretical approach for T-lymphocyte monitoring of autologous cancer vaccine therapy using autologous HLA-class I and HLA-class II constructs.
Cancer biotherapy & radiopharmaceuticals 2004;19(4):405-10.
2003: Patric M Schiltz; Robert O Dillman
Serum cytokines in metastatic melanoma patients treated with an autologous tumor vaccine.
Cancer biotherapy & radiopharmaceuticals 2003;18(6):879-86.
2003: Robert O Dillman; Carolyn S Hendrix
Unique aspects of supportive care using monoclonal antibodies in cancer treatment.
Supportive cancer therapy 2003;1(1):38-48.
2003: Robert O Dillman; Gamini Soori; Carol DePriest; Shankar K Nayak; Linda D Beutel; Patric M Schiltz; Cristina de Leon; Andrew O'connor
Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research group.
Cancer biotherapy & radiopharmaceuticals 2003;18(5):727-33.
2003: Robert O Dillman; Michael C Wiemann; Shankar K Nayak; Cristina DeLeon; K Hood; Carol DePriest
Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(4):367-73.
2003: Robert O Dillman; Andrew O'connor; Linda Simpson; Neil M Barth; Louis A VanderMolen; Peter Vanderplas
Does continuous-infusion interleukin-2 increase survival in metastatic melanoma?
American journal of clinical oncology 2003;26(2):141-5.
2002: Carolyn Hendrix; Cristina de Leon; Robert O Dillman
Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
Clinical journal of oncology nursing 2002;6(3):144-8.
2002: Gamini Soori; Robert O Dillman; Michael C Wiemann; James J Stark; Fritz Tai; Carol DePriest; Curtis K Church; Richard Schulof
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Cancer biotherapy & radiopharmaceuticals 2002;17(2):165-73.
2002: Robert O Dillman; Linda D Beutel; Neil M Barth; Cristina de Leon; Andrew O'connor; Carol DePriest; Shankar K Nayak
Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
Cancer biotherapy & radiopharmaceuticals 2002;17(1):51-66.
2002: Louis A VanderMolen; Patrick F Sheehy; Robert O Dillman
Successful treatment of transitional cell carcinoma of the urethra with chemotherapy.
Cancer investigation 2002;20(2):206-7.
2001: C C Malone; Patric M Schiltz; A D Mackintosh; Linda D Beutel; F S Heinemann; Robert O Dillman
Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
Cancer biotherapy & radiopharmaceuticals 2001;16(5):381-90.
2001: Robert O Dillman; Cristina DeLeon; Linda D Beutel; Neil M Barth; Lee S Schwartzberg; L E Spitler; D H Garfield; Andrew O'connor; Shankar K Nayak
Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.
Critical reviews in oncology/hematology 2001;39(1-2):115-23.
2001: Robert O Dillman; Linda D Beutel; Cristina de Leon; Shankar K Nayak
Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer.
Cancer biotherapy & radiopharmaceuticals 2001;16(3):205-11.
2001: Robert O Dillman; Neil M Barth; Louis A VanderMolen; D H Garfield; Cristina de Leon; Andrew O'connor; Khosrow Mahdavi; Shankar K Nayak
Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Cancer biotherapy & radiopharmaceuticals 2001;16(1):47-54.
2001: Robert O Dillman
Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments.
Cancer investigation 2001;19(8):833-41.
2001: Robert O Dillman; W M Shea; D F Tai; Khosrow Mahdavi; Neil M Barth; B R Kharkar; M M Poor; Curtis K Church; Carol DePriest
Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma.
Neuro-oncology 2001;3(1):35-41.
2000: Robert O Dillman; Gamini Soori; Michael C Wiemann; Richard Schulof; T W Dobbs; R H Ruben; Carol DePriest; Curtis K Church
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Cancer biotherapy & radiopharmaceuticals 2000;15(5):487-94.
2000: Robert O Dillman; Linda D Beutel; Andrew N Cornforth; Shankar K Nayak
Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
Cancer biotherapy & radiopharmaceuticals 2000;15(2):161-8.
2000: Shankar K Nayak; S Kakati; Shashi R Harvey; C C Malone; Andrew N Cornforth; Robert O Dillman
Characterization of cancer cell lines established from two human metastatic breast cancers.
In vitro cellular & developmental biology. Animal 2000;36(3):188-93.
2000: Robert O Dillman; Sherri Chico
Radiologic tests after a new diagnosis of breast cancer.
Effective clinical practice : ECP 2000;3(1):1-6.
1999: Robert O Dillman; Shankar K Nayak; J V Brown; Khosrow Mahdavi; Linda D Beutel
The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer.
Cancer biotherapy & radiopharmaceuticals 1999;14(6):443-9.
1999: Robert O Dillman
What to do with IL-2?
Cancer biotherapy & radiopharmaceuticals 1999;14(6):423-34.
1999: Robert O Dillman
Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer.
Cancer biotherapy & radiopharmaceuticals 1999;14(1):5-10.
1999: C Malone; Patric M Schiltz; Shankar K Nayak; M W Shea; Robert O Dillman
Combination interferon-alpha2a and 13-cis-retinoic acid enhances radiosensitization of human malignant glioma cells in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):417-23.
1999: Shankar K Nayak; Patric M Schiltz; Robert O Dillman
Modulation of renal carcinoma cells in vitro: comparison after transduction with retroviral vector containing a human IFN-gamma gene versus incubation with soluble IFN-gamma.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(1):49-58.
1998: Robert O Dillman; Shankar K Nayak; Neil M Barth; Cristina DeLeon; Lee S Schwartzberg; L E Spitler; Curtis K Church; Andrew O'connor; Linda D Beutel
Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
Cancer biotherapy & radiopharmaceuticals 1998;13(3):165-76.
1998: John P Micha; Mark A Rettenmaier; Robert O Dillman; P Fraser; Connie L Birk; John V Brown
Single-dose dexamethasone paclitaxel premedication.
Gynecologic oncology 1998;69(2):122-4.
1998: James J Stark; Robert O Dillman; Richard Schulof; Michael C Wiemann; Neil M Barth; P J Honeycutt; Gamini Soori
Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
Cancer 1998;82(9):1677-81.
1997: Patric M Schiltz; Linda D Beutel; Shankar K Nayak; Robert O Dillman
Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(5):377-86.
1997: Robert O Dillman; Michael C Wiemann; Louis A VanderMolen; MJ Bury; Carol DePriest; Curtis K Church
Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group).
Cancer biotherapy & radiopharmaceuticals 1997;12(4):249-55.
1997: Robert O Dillman; Curtis K Church; Neil M Barth; R K Oldham; Michael C Wiemann
Long-term survival after continuous infusion interleukin-2.
Cancer biotherapy & radiopharmaceuticals 1997;12(4):243-8.
1997: Robert O Dillman; R Crispin; R K Oldham
The Cancer Biotherapy Research Group [CBRG], formerly the National Biotherapy Study Group [NBSG]: a 10-year perspective.
Cancer biotherapy & radiopharmaceuticals 1997;12(4):229-42.
1997: Robert O Dillman; S R Hurwitz; Patric M Schiltz; Neil M Barth; Linda D Beutel; Shankar K Nayak; Andrew O'connor
Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer.
Cancer biotherapy & radiopharmaceuticals 1997;12(2):65-71.
1997: Robert O Dillman; Michael C Wiemann; MJ Bury; Curtis K Church; Carol DePriest
Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group.
Cancer biotherapy & radiopharmaceuticals 1997;12(1):5-11.
1996: Robert O Dillman; James Herndon; S L Seagren; W L Eaton; Mark R Green
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Journal of the National Cancer Institute 1996;88(17):1210-5.
1996: Robert O Dillman; L A Vandermolen; Neil M Barth; K J Bransford
Malignant melanoma and pregnancy ten questions.
The Western journal of medicine 1996;164(2):156-61.
1995: Robert O Dillman; Michael C Wiemann; R K Oldham; G Soori; M Bury; R Hafer; Curtis K Church; Carol DePriest
Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group.
Cancer biotherapy 1995;10(4):265-71.
1995: Robert O Dillman; Neil M Barth; K Mahdavi; L A VanderMolen; Shankar K Nayak; A O'Connor
The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center.
Cancer biotherapy 1995;10(1):25-36.
1994: Robert O Dillman
The clinical experience with interleukin-2 in cancer therapy.
Cancer biotherapy 1994;9(3):183-209.
1994: Robert O Dillman; T Williams
Value of prostate cancer screening in a comprehensive community cancer center.
Cancer investigation 1994;12(5):456-62.
1993: Harvey Kreisman; A Lisbona; L Olson; Kathleen J Propert; C Modeas; Robert O Dillman; S L Seagren; Mark R Green
Effect of radiologic stage III substage on nonsurgical therapy of non-small cell lung cancer.
Cancer 1993;72(5):1588-96.
1993: Robert O Dillman; Shankar K Nayak; Linda D Beutel
Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(1):65-9.
1993: Robert O Dillman; C Church; R K Oldham; William West; Lee Schwartzberg; Robert Birch
Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.
Cancer 1993;71(7):2358-70.
1992: S E Halpern; Robert O Dillman; D Amox; P L Hagan; R Burks; J Dillman; B Perdikakis; B Merchant; J Frincke; S Schweighardt
Detection of occult tumor using indium 111-labeled anticarcinoembryonic antigen antibodies.
Archives of surgery (Chicago, Ill. : 1960) 1992;127(9):1094-100.
1992: Robert O Dillman; J A Koziol
Phase I cancer trials: limitations and implications.
Molecular biotherapy 1992;4(3):117-21.
1992: Robert O Dillman; K P Ryan; J B Dillman; Daniel L Shawler; R Maguire
WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients.
Molecular biotherapy 1992;4(1):10-4.
1991: Robert O Dillman; R K Oldham; N M Barth; R J Cohen; D R Minor; Robert Birch; J R Yannelli; J R Maleckar; A Sferruzza; J Arnold
Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial.
Cancer 1991;68(1):1-8.
1991: Robert O Dillman; R K Oldham; Kurt Tauer; D W Orr; Neil M Barth; G Blumenschein; J Arnold; Robert Birch; William West
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1233-40.
1991: R K Oldham; Robert O Dillman; J R Yannelli; N M Barth; J R Maleckar; A Sferruzza; R J Cohen; D R Minor; L Spitler; Robert Birch
Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.
Molecular biotherapy 1991;3(2):68-73.
1990: Robert O Dillman
Rationales for combining chemotherapy and biotherapy in the treatment of cancer.
Molecular biotherapy 1990;2(4):201-7.
1990: Robert O Dillman; S L Seagren; Kathleen J Propert; J Guerra; W L Eaton; M C Perry; RW Carey; E F Frei; Mark R Green
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
The New England journal of medicine 1990;323(14):940-5.
1990: Robert O Dillman; R K Oldham; Neil M Barth; Robert Birch; J Arnold; William West
Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.
Journal of the National Cancer Institute 1990;82(16):1345-9.
1989: Robert O Dillman; D E Johnson; J Ogden; D Beidler
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
Molecular biotherapy 1989;1(5):250-5.
1988: K P Ryan; Robert O Dillman; S J DeNardo; G L DeNardo; J Beauregard; P L Hagan; D G Amox; M L Clutter; K G Burnett; C M Rulot
Breast cancer imaging with In-111 human IgM monoclonal antibodies: preliminary studies.
Radiology 1988;167(1):71-5.
1988: Robert O Dillman; J C Beauregard; M Jamieson; D Amox; S E Halpern
Toxicities associated with monoclonal antibody infusions in cancer patients.
Molecular biotherapy 1988;1(2):81-5.
1987: Robert O Dillman; J Beauregard; I Royston; M I Zavanelli
Phase II trial of thymosin fraction 5 and thymosin alpha 1.
Journal of biological response modifiers 1987;6(3):263-7.
1987: Robert O Dillman; J Beauregard; K P Ryan; P L Hagan; M Clutter; D Amox; J M Frincke; Richard Bartholomew; K G Burnett; George David
Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies.
NCI monographs : a publication of the National Cancer Institute 1987;(3):33-6.
1986: Robert O Dillman; J Beauregard; Daniel L Shawler; S E Halpern; M Markman; K P Ryan; S M Baird; M Clutter
Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma.
Journal of biological response modifiers 1986;5(5):394-410.
1986: Daniel L Shawler; J Beauregard; S E Halpern; S M Baird; Robert O Dillman
Tissue distribution and serum kinetics of T101 monoclonal antibody during passive anti-cancer therapy.
Clinical immunology and immunopathology 1986;41(1):43-54.
1986: Robert O Dillman; D L Shawler; D E Johnson; D L Meyer; J A Koziol; J M Frincke
Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin.
Cancer research 1986;46(10):4886-91.
1986: P L Hagan; S E Halpern; Robert O Dillman; Daniel L Shawler; D E Johnson; A Chen; L Krishnan; J Frincke; Richard Bartholomew; G S David
Tumor size: effect on monoclonal antibody uptake in tumor models.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1986;27(3):422-7.
1986: Robert O Dillman; J C Beauregard; S E Halpern; M Clutter
Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies.
Journal of biological response modifiers 1986;5(1):73-84.
1985: S E Halpern; Robert O Dillman; K F Witztum; J F Shega; P L Hagan; W M Burrows; J B Dillman; M L Clutter; R E Sobol; J M Frincke
Radioimmunodetection of melanoma utilizing In-111 96.5 monoclonal antibody: a preliminary report.
Radiology 1985;155(2):493-9.
1984: Daniel L Shawler; M C Miceli; S B Wormsley; I Royston; Robert O Dillman
Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101.
Cancer research 1984;44(12 Pt 1):5921-7.
1984: Robert O Dillman; J C Beauregard; R E Sobol; I Royston; Richard Bartholomew; P S Hagan; S E Halpern
Lack of radioimmunodetection and complications associated with monoclonal anticarcinoembryonic antigen antibody cross-reactivity with an antigen on circulating cells.
Cancer research 1984;44(5):2213-8.
1984: Robert O Dillman; J A Koziol; M I Zavanelli; J C Beauregard; B L Halliburton; M C Glassy; I Royston
Immunoincompetence in cancer patients. Assessment by in vitro stimulation tests and quantification of lymphocyte subpopulations.
Cancer 1984;53(7):1484-91.
1983: Robert O Dillman; J C Beauregard; J W Lea; M R Green; RE Sobol; I Royston
Chronic lymphocytic leukemia and other chronic lymphoid proliferations: surface marker phenotypes and clinical correlations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1983;1(3):190-7.
1983: Robert O Dillman; J C Beauregard; M I Zavanelli; B L Halliburton; S Wormsley; I Royston
In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin alpha 1.
Journal of biological response modifiers 1983;2(2):139-49.
1982: Robert O Dillman; Daniel L Shawler; RE Sobol; H A Collins; J C Beauregard; S B Wormsley; I Royston
Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia.
Blood 1982;59(5):1036-45.